Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chronic pain treatments more effective when taken together

01.04.2005


People suffering from chronic, debilitating pain caused by nerve damage or disease report better pain relief at lower doses of a combined drug treatment than from either drug administered individually, a new Queen’s study funded by the Canadian Institutes of Health Research (CIHR) shows.



When given a combination of the anti-seizure drug gabapentin and the opioid morphine, patients with two different types of neuropathic pain experienced lower pain intensity than when they received either of the drugs individually. As well, significantly lower doses of gabapentin and morphine were required during combination treatment than during treatment with either drug alone.

“We now have the first clinical evidence that combining these drugs provides better pain relief, with comparable side effects,” says lead researcher Dr. Ian Gilron, Director of Clinical Pain Research for Queen’s Departments of Anesthesiology, and Pharmacology & Toxicology, and an anesthesiologist at Kingston General Hospital. “This new treatment approach has the potential to dramatically improve quality of life for people suffering from neuropathic pain, a condition that has puzzled health care workers for years because it is often experienced in areas of the body which appear uninjured.”


Results of the study are published in the March 31 edition of the New England Journal of Medicine.

Also on the team from Queen’s are Joan Bailey (Anesthesiology), Dongsheng Tu (Mathematics and Statistics), Ronald Holden (Psychology,) Robyn Houlden (Medicine); and from Dalhousie University’s Departments of Medicine and Chemistry, Donald Weaver.

“This is exciting news for the health research community in Canada,” says Dr. Rémi Quirion, Scientific Director of CIHR’s Institute of Neurosciences, Mental Health and Addiction. “It is a great achievement for Dr. Gilron and his team, but most importantly, it is a critical research finding for Canadians whose chronic pain may be eased by this research. Dr. Gilron and his team are a shining example of CIHR-funded researchers taking research knowledge from the bench to the bedside.”

Although the research focused on two specific types of neuropathic pain – diabetic neuropathy and postherpetic neuralgia – the methods used in this trial could be employed in studying other chronic conditions such as cancer, spinal disk disease, and the pain experienced after chemotherapy and mastectomies, Dr. Gilron notes. “The numbers of people affected are staggering, and the impact of the problem is devastating and costly.”

Diabetic neuropathy occurs in diabetes patients who experience a constant, burning pain, often in the soles of their feet, that isn’t associated with obvious tissue injury. It is sometimes accompanied by electrical shooting pains up the foot and into the lower leg.

Postherpetic neuralgia results from a re-activation of the virus that causes chicken pox, and usually develops after someone has a herpes zoster or “shingles” infection in an isolated part of the body. In 10 to 20 per cent of people afflicted with herpes zoster, the pain doesn’t go away after the rash disappears. Instead it continues to be felt as a burning sensation and often makes normal touch excruciatingly painful.

Both conditions are due to nerve damage and/or injury, and are associated with the experience of pain in an apparently uninjured area, Dr. Gilron explains. Most of the current treatments for this condition cause side effects, which limit the drug dosage a person can tolerate.

“What we need to do clinically is to achieve a balance between side effects and pain relief,” says the Queen’s anesthesiologist. “The purpose of this study was to evaluate two different drugs for chronic pain, and to carefully measure both the pain-relieving effects and the side effects.”

The clinical trial compared a combination of morphine and gabapentin to each drug alone, as well as to a placebo, in a group of patients with either diabetic neuropathy or postherpetic neuralgia. All the patients received all four treatments.

The results showed that pain intensity was significantly lower with the combination treatment than with either drug alone, or with the placebo. As well, the team found that significantly lower doses of morphine and gabapentin were taken during the combination treatment than during treatment with either drug alone.

“For a lot of these people the pain is unrelenting and it’s unclear when or if it will improve,” says Dr. Gilron. “This new evidence showing that combination treatment provides better pain relief, with comparable side effects, opens the door to exciting possibilities for chronic pain management.”

The Canadian Institutes of Health Research is the Government of Canada’s premier agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.

Contacts:

Nancy Dorrance, Queen’s News & Media Services, 613.533.2869
Therese Greenwood, Queen’s News & Media Services, 613.533.6907
Janet Weichel, CIHR Communications, 613.941.4563

Nancy Dorrance | EurekAlert!
Further information:
http://www.queensu.ca

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>